Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib

The cholesterol ester transfer protein (CETP) inhibitor dalcetrapib has been under evaluation for its potential to prevent cardiovascular (CV) events for almost two decades. The current clinical development program, representing new advances in precision medicine and focused on a genetically defined...

Descripción completa

Detalles Bibliográficos
Autores principales: Black, Donald M., Bentley, Darren, Chapel, Sunny, Lee, Jongtae, Briggs, Emily, Heinonen, Therese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182459/
https://www.ncbi.nlm.nih.gov/pubmed/29730761
http://dx.doi.org/10.1007/s40262-018-0656-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182459/
https://www.ncbi.nlm.nih.gov/pubmed/29730761
http://dx.doi.org/10.1007/s40262-018-0656-3

Ejemplares similares